Medicine details

ImageDialiptin-M 500
NameDialiptin-M 500
DosageTablet
Generic NameMetformin Hydrochloride + Vildagliptin
Classes Antidiabetic Agent
Metabolic Agent
Antidiabetic combination
Diseases Type 2 Diabetes Mellitus
Hormonal Disorder
CompanyDrug International Ltd.

Drug Package Details

Strength500 mg + 50 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack14
Price per pack224.70
Cost per pack197.74
Package unit14 tabs strip
Price per unit16.05
Cost per unit14.12
Discount0
Coupon
Remarks

Metformin Hydrochloride + Vildagliptin

Metformin Hydrochloride + Vildagliptin is a combination of two antidiabetic drugs from the classes Biguanides and Dipeptidyl peptidase-4 inhibitor. Metformin is a hypoglycemic agent belonging to the class Biguanides. Metformin enhances insulin sensitivity by boosting peripheral glucose uptake and utilization, decreasing hepatic glucose synthesis, and decreasing intestinal glucose absorption. Vildagliptin works by increasing the concentration of incretins in the blood which ultimately results in the increased secretion of insulin.

Metformin Hydrochloride + Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 

Side effects associated with Metformin Hydrochloride + vildagliptin include-

  • Diarrhea
  • Upper respiratory tract infection
  • Hypoglycemia
  • Headache
  • Pharyngitis
  • Indigestion
  • Asthenia
  • Do not use Metformin+vildagliptin in patients with hepatic disease.
  • There have been post-marketing reports of acute renal failure, sometimes requiring dialysis. Before initiating Metformin+vildagliptin and at least annually thereafter, assess renal function and verify as normal.
  • There have been post-marketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue Metformin+vildagliptin.
  • Measure hematologic parameters annually.
  • Warn patients against excessive alcohol intake.
  • May need to discontinue Metformin+vildagliptin and temporarily use insulin during periods of stress and decreased intake of fluids and food as may occur with fever, trauma, infection or surgery. 
  • Promptly evaluate patients previously controlled on Metformin+vildagliptin who develop laboratory abnormalities or clinical illness for evidence of ketoacidosis or lactic acidosis.
  • When used with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia. 
  • There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with vildagliptin (one of the components of Metformin+vildagliptin), such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. In such cases, promptly stop Metformin+vildagliptin, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.
  • There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Metformin+vildagliptin or any other anti-diabetic drug

Contraindication

Contraindicated in Patients hypersensitive to Metformin or Sitagliptin or similar drug such as-

Contraindicated in-

  • severe liver disease
  • severe kidney disease
  • metabolic acidosis
  • lactic acidosis
  • patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials